Key result
Cancer genetics link to VTE risk, with high-grade gliomas reaching 30% and IDH1 mutations correlating inversely.
Why the study?
Does cancer genetic profile influence the risk of thrombosis in patients with cancer?
Does cancer genetic profile influence the risk of thrombosis in patients with cancer?
Specific cancer genetic profiles, such as IDH1 and STK11 mutations, appear to influence the risk of venous thromboembolism, though large-scale validation is required before clinical integration.
Answers are grounded in this paper and cite their sources.
May refine VTE risk stratification in select cancers; leaves open prospective validation before guiding prophylaxis.
) and antiangiogenic therapies may elevate thrombotic risk, warranting further study. High-grade gliomas, particularly glioblastomas, present VTE rates up to 30 %, driven by podoplanin-induced platelet aggregation. IDH1 mutations inversely correlate with thrombosis, highlighting its protective role. Emerging evidence suggests that agnostic biomarkers such as STK11 mutations influence VTE risk across tumor types, while others like KRAS, MET and BRCA mutations show inconclusive results. Large-scale validation studies are imperative to integrate molecular profiles into clinical practice. Until then, management decisions should be individualized, balancing the thrombotic risks with oncologic considerations.
No takes yet. Share an insight, caveat, or question.
Mateo et al. (2025) conducted a review in Cancer-associated thrombosis. Cancer genetic profiles (e.g., IDH1, STK11 mutations) was evaluated on Venous thromboembolism (VTE) risk. Cancer genetic profiles influence VTE risk across tumor types, with high-grade gliomas presenting VTE rates up to 30%, while IDH1 mutations inversely correlate with thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: